Prediabetes and Gout Risk: The Role of Metformin Use and Longitudinal Serum Urate Analysis
View/ Open
Thesis manuscript 04-17-2024 - Javier Marrugo - clean version updated.pdf (5.532Mb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
Marrugo, Javier
Metadata
Show full item recordCitation
Marrugo, Javier. 2024. Prediabetes and Gout Risk: The Role of Metformin Use and Longitudinal Serum Urate Analysis. Master's thesis, Harvard Medical School.Abstract
Background:Despite the strong association between gout and prediabetes, the role of antidiabetic medications in managing gout among individuals with prediabetes remains uncertain. We estimated the incidence of gout and additionally compared the survival distribution of gout development in prediabetic patients starting metformin with prediabetic patients not using any antidiabetic treatments.
Methods:
We conducted a new-user, propensity score-matched cohort study using electronic health record data from an academic health system (2007-2022). Prediabetics were defined based on haemoglobin A1c levels. Metformin users were identified and followed from the first metformin prescription date. Non-users of antidiabetic medications were matched to metformin users based on propensity score and the start of follow-up. The primary outcome was incident gout. Cox proportional hazards models estimated the hazard ratio for metformin. Linear regression analyses assessed the association between metformin use and changes in serum urate (SU) or C-reactive protein (CRP).
Results:
We identified 25,064 prediabetics and propensity score-matched 1,154 metformin initiators to 13,877 non-users. Baseline characteristics were well balanced (all standardized mean differences .1). Median follow-up was 3.9 years. The incidence rate of gout per 1000 person-years was lower in metformin users 7.1 (95% CI 5.1 to 10) compared to non-users 9.5 (95% CI 8.8 to 10.2). Metformin initiation was associated with a reduced relative risk of gout (HR 0.68, 95% CI 0.48 to 0.96). No relationship was found between metformin use and changes in SU or CRP.
Conclusions:
Metformin use was associated with a lower risk of gout among patients with prediabetes, suggesting that treatment with metformin may have a role in lowering the risk of gout in individuals with prediabetes.
Keywords: Gout, incidence, crystal arthropathies
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37378397
Collections
Contact administrator regarding this item (to report mistakes or request changes)